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The protozoan parasite, Trypanosoma cruzi, causes the most prevalent parasitic infection in the American
continent. It gives rise to life-long infection in humans and results in severe cardiomyopathy or other life-
threatening manifestations (Chagas disease) in 30% of those infected. Animal models and clinical stud-
ies indicate that etiological treatment of the infection reduces the risk of developing the disease manifes-
tations. Unfortunately, the existing chemotherapeutics have suboptimal antiparasitic activity and cause
signiﬁcant side effects in many patients, thus better anti-trypanosomal drugs are greatly needed. The ste-
rol biosynthesis pathway has received attention as a target for the development of new drugs for Chagas
disease. In particular, inhibitors of sterol 14-demethylase (CYP51) are shown to be extremely active on T.
cruzi in vitro and in animal models. Antifungal drugs (i.e. azoles) in clinical use or in clinical studies have
been extensively tested preclinically on T. cruzi with posaconazole and ravuconazole demonstrating the
most promising activity. As a result, posaconazole and a pro-drug of ravuconazole (E1224) are currently
being evaluated in Phase II studies for Chagas disease. Additional CYP51 inhibitors that are speciﬁcally
optimized for anti-T. cruzi activity are in development by academia. These represent an alternative to pro-
prietary antifungal drugs if the latter fall short in clinical trials or are too expensive for widespread clin-
ical use in disease endemic countries. The research over the next few years will help deﬁne the role of
CYP51 inhibitors, alone or in combination with other drugs, for managing patients with Chagas disease.
 2012 Australian Society for Parasitology Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction to Chagas disease
The etiologic agent of Chagas disease, the protozoan Trypano-
soma cruzi (T. cruzi), is primarily transmitted to humans by blood
feeding Triatomine bugs. Vectorial transmission is conﬁned to the
American continent, whereas infection by blood transfusion or by
mother-to-baby transmission occurs wherever individuals harbor-
ing this chronic infection reside or immigrate. Approximately 8–10
million people are infected in Latin America making it the most
prevalent parasitic disease in the American continent and the ﬁrst
cause of heart disease and heart deaths among poor rural popula-
tions in Latin America (Rassi et al., 2010). An estimated 300,000 in-
fected persons live in the United States, mostly immigrants from
Latin America. A comparable number are living with this parasite
in Europe (Gascon et al., 2010; Leslie, 2011).
T. cruzi infects a wide range of mammalian hosts where it estab-
lishes a chronic infection. During the initial acute phase, the para-Published by Elsevier Ltd.
: +1 206 685 6045.
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Open acsite rapidly cycles between a replicative intracellular stage
(amastigotes) and a non-replicative bloodstream stage (trypom-
astigotes), successfully disseminating throughout the body. The
protozoan is capable of infecting diverse host cell types where it
replicates freely within the cytoplasm (as opposed to within a vac-
uolar organelle, which is the case for the related parasites of the
Leishmania genus). In an immunocompetent host, the infection is
controlled by a mixed immune response involving both humoral
and cellular effector mechanisms but, in the large majority of cases,
the parasite is not eradicated leading to life-long infections. During
the acute stage, lasting just a few weeks, persons have ﬂu-like
symptoms, and are rarely diagnosed or treated; this stage has low
(ca. 5%) mortality and leads to an initially asymptomatic (‘‘indeter-
minate’’) phase, which for 60–70% of infected persons lasts for the
rest of their lives. In the remaining 30–40% of individuals, chronic
Chagas disease manifests within 1–3 decades, primarily involving
the heart, gastrointestinal tract, or nervous system. Chagasic car-
diomyopathy, which results from a chronic inﬂammatory process
triggered and sustained by the persistence of the parasite (Urbina,
2010; Marin-Neto et al., 2007; Rassi et al., 2010), is associated with
malignant arrhythmias, embolic events, and/or rapidly progressive
congestive heart failure and death. Since persons are often infected
as children, the morbidity and mortality from Chagas disease typi-
cally strikes during the prime adult years in people’s lives.cess under CC BY-NC-ND license.
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oped empirically over 40 years ago. These are nitroheterocyclic
compounds, benznidazole and nifurtimox, that act by generating
free radicals or reductive stress in T. cruzi cells. When used during
acute infection, they cure up to 80% of infections, but the vast
majority of patients are not diagnosed until they are in the chronic
stage where, unfortunately, parasitological cure rates with the
drugs, as assessed by conventional serology, are less than 20%.
Many clinicians are reluctant to use these drugs because of the
unfavorable risk-to-beneﬁt proﬁles due to side effects such as
allergic dermopathy, vomiting, psychosis, and neuropathy (Urbina
and Docampo, 2003; Urbina, 2010). Clinical data and animal mod-
els indicate that parasitological cures or reduction of the parasite
burden of the patients are associated with improved clinical out-
comes (Viotti et al., 2006, 2011). As a consequence, new drugs with
greater antiparasitic activity and improved safety proﬁles would
potentially make it possible to treat the scores of individuals har-
boring both acute and chronic T. cruzi infections, to prevent or mit-
igate the manifestations of chronic Chagas disease.2. Sterol biosynthesis and CYP51 of T. cruzi
Sterols are essential lipid components of eukaryotic mem-
branes. These molecules are important regulators of membrane
physical properties, such as permeability and ﬂuidity, and also
have essential roles in aerobic metabolism, regulation of cell cycle,
sterol uptake, and sterol transport (Daum et al., 1998). The initial
steps in cholesterol biosynthesis also lead to the synthesis of other
important molecules, including dolichol, ubiquinone, isopentylad-
enine, heme A, and prenylated proteins. The ﬁnal products of sterol
biosynthesis vary among eukaryotes with mammals producing
cholesterol, while fungi plants and protozoa produce 24-alkyl ster-
ols, with distinct modiﬁcations of both the steroid nucleus and the
alkyl side chain for each phylogenetic group. The sterol biosynthe-
sis pathway of T. cruzi epimastigotes is illustrated in Fig. 1. T. cruzi
is similar to fungi in its sterol composition, with ergosterol (24-
methyl-5,7,22-trien-3b-ol) and its 24-ethyl analog (24-ethyl-cho-
lesta-5,7,22-trien-3b-ol) being the major mature sterols in the epi-
mastigote stage (within the insect host) (Fig. 1) (Furlong, 1989;
Korn et al., 1969; Urbina et al., 1998; Liendo et al., 1998). The major
sterols produced by the amastigote stage (inside the mammalian
host cells) are fungisterol (ergosta-7-en-3b-ol) and its 24-ethyl
analog (24-ethyl-cholesta-7-en-3b-ol) (Liendo et al., 1999)
(Fig. 2). Although T. cruzi incorporates its mammalian host sterols
(primarily cholesterol) into its membranes, it has an essential
requirement for de novo sterol synthesis for survival in all stages
of its life cycle and is highly susceptible to sterol biosynthesis
inhibitors (Liendo et al., 1998, 1999; Urbina et al., 1998).
Synthesis of the major animal sterol (cholesterol) and the 24-al-
kyl-sterols in fungi, protozoa and plants, requires removal of the
14a-methyl groups from sterol precursors. The reaction is cata-
lyzed by a microsomal cytochrome P450, the sterol C14-demethyl-
ase (CYP51). In mammals and yeast, where the substrate is
lanosterol (Fig. 1), the enzyme is frequently called the lanosterol
14a-demethylase. In T. cruzi, new data suggests that the preferred
substrate is not lanosterol, but rather eburicol (24-methylene-
dihydrolanosterol) (Lepesheva et al., 2006) (Fig. 1). CYP51 speciﬁ-
cally catalyzes the removal of the C14 methyl group from the sterol
scaffold through three successive oxidations resulting in decarbox-
ylation, releasing formic acid (Fischer et al., 1989). During catalysis,
the active-site heme iron is reduced by a P450-reductase enzyme
utilizing NADPH, from the resting ferric (Fe+++) state to active fer-
rous (Fe++) state; the resting state is regenerated in each cycle by
the transfer of electrons to oxygen and the incorporation of this
atom in the C14 substituent of the sterol substrate (Lepeshevaet al., 2011). Inhibition of cytochrome P450 enzymes by azole
drugs (discussed below) results from coordination of the azole
nitrogen to the heme iron, with the lipophilic ligand attached to
the azole occupying the binding site for the substrate. These inhib-
itors prevent both binding of the substrate and oxygen activation
(Walker et al., 1993). Recent crystal structures of trypanosomal
CYP51 bound to substrate and inhibitors have provided news in-
sights into the details of the catalytic site of this enzyme (Chen
et al., 2010; Lepesheva et al., 2010a,b; Hargrove et al., 2011).3. History of azole drug testing on T. cruzi
Azole derivatives with selective activity against fungal CYP51
(devoid of signiﬁcant activity against the human ortholog enzyme)
have been used as ﬁrst line antifungal drugs since the 1970s. The
ﬁrst description of activity of CYP51 inhibitors on T. cruzi was re-
ported by Docampo and colleagues thirty years ago (Docampo,
1981). This report described growth inhibitory activity and ultra-
structural alterations on T. cruzi cells produced by the topical anti-
fungal azoles miconazole and econazole. Numerous studies
followed over the years with the theme of testing antifungal
CYP51 inhibitors against T. cruzi. The earlier generation imidazoles
(e.g. ketoconazole, miconazole, clotrimazole) and triazoles (e.g.
ﬂuconazole and itraconazole) were found to have potent and selec-
tive in vitro activity, but were not curative in animal models of T.
cruzi infection (Buckner, 2008). Referred to collectively as ‘‘azoles’’,
these drugs have profound effects on the sterol composition of
cultured T. cruzi indicating that their mechanism of action is
through disruption of sterol biosynthesis, presumably by binding
to T. cruzi CYP51, since the block results in accumulation of 14-
methylated sterols (Urbina et al., 1996, 1998; Liendo et al.,
1999). Additional studies have shown direct binding of these com-
pounds to puriﬁed recombinant T. cruzi CYP51 as well as inhibition
of its enzymatic function in vitro (Buckner et al., 2003; Lepesheva
et al., 2007).
As new azole drugs have been developed by pharmaceutical
companies to combat fungal diseases, these in turn have been
tested for activity against T. cruzi. The experimental azole drug,
D0870 was the ﬁrst to show cure of mice chronically infected with
T. cruzi (Urbina et al., 1996). Unfortunately, D0870 was discontin-
ued in clinical trials (of fungal infections) due to untoward side ef-
fects (Williams and Denning, 2001). The second-generation azole
antifungal drug, voriconazole, has comparatively weak anti-T. cruzi
activity (Buckner, 2008) and has not been pursued for clinical
development. Posaconazole (Noxaﬁl, Merck; Fig. 3), on the other
hand, is the most potent and efﬁcacious azole drug against T. cruzi
yet to be identiﬁed (Liendo et al., 1999; Urbina et al., 1998; Molina
et al., 2000). Clinically approved in 2006 for the prophylaxis and
treatment of invasive fungal infections due to its broad-spectrum
antifungal activity and excellent safety proﬁle, posaconazole could
potentially be repurposed for use in Chagas disease, thereby avoid-
ing substantial costs and risks of developing a new chemical entity.
It is the only clinically approved azole drug that is curative in the
chronic murine model of T. cruzi infection and has potent activity
against benznidazole- and nifurtimox-resistant T. cruzi strains,
even in immunocompromised animals (Molina et al., 2000). The
in vitro potency of posaconazole (subnanomolar concentrations
against intracellular amastigotes) is probably due to its very tight
binding to T. cruzi CYP51, which involves direct interactions with
13 amino acid side chains in the active site and 12 in the hydropho-
bic substrate access channel and has, in fact, a stabilizing effect on
the tertiary structure of the protein (Fig. 4) (Lepesheva et al.,
2010a; Chen et al., 2010). These facts, combined with the favorable
pharmacokinetic characteristics (including large volumes of distri-
bution and long terminal half life) of the drug in humans and
Fig. 1. Sterol biosynthesis of T. cruzi epimastigotes (adapted from Lepesheva et al., 2011). The T. cruzi sterol-14-demethylase (labeled CYP51) prefers eburicol as substrate
(Lepesheva et al., 2006).
Fig. 2. The main sterols of intracellular T. cruzi amastigotes: fungisterol and its 24-
ethyl analog.
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cruzi activity when compared with other clinically used azoles.
Furthermore, it has recently been demonstrated that posaconazole
and other lipophilic drugs accumulate in the membranes of cells
and, as a result, the effective local concentrations of these drugs
that interact with their membrane-bound CYP51 targets are in fact
much higher than their overall cell or tissue levels (Campoli et al.,
2011). A recent case report from Spain described the successful use
of posaconazole to treat a patient with chronic T. cruzi infection,
compounded by immunosuppressive treatment required to control
systemic lupus erythematosus, who had failed benznidazole che-
motherapy (Pinazo et al., 2010). These data have led to two
proof-of-concept phase II clinical studies with posaconazole for
the speciﬁc treatment of Chagas disease: the ﬁrst was launched
in October 2010 at the Vall d’Hebron Hospital in Barcelona, Spain(http://www.clinicaltrials.gov/ct2/show/NCT01162967?term=
posaconazole,+Chagas+disease&rank=1) and a second one, spon-
sored by Merck & Co (http://www.clinicaltrials.gov/ct2/show/
NCT01377480?term=Chagas&rank=1) (Clayton, 2010), began
recruiting patients in Argentina on the July 2011. Such studies will
take us a big step closer to deﬁning the role of this drug for treating
Chagas disease. Unfortunately, posaconazole is an extremely
expensive drug, so even if it is shown to be efﬁcacious in humans,
there is looming concern that it may be difﬁcult to make it
available to patients living in resource limited settings (Urbina,
2011).
Other azole antifungal drugs that have been researched include
albaconazole, TAK-187, and ravuconazole (Guedes et al., 2004;
Urbina et al., 2003a,b; Corrales et al., 2005; Diniz et al., 2010). Rav-
uconazole (Eisai Co., Tokyo, Japan; Fig. 3) deserves special mention.
It is highly active in vitro against T. cruzi (minimum inhibitory con-
centration of 1 nM against intracellular amastigotes), but has sup-
pressive, rather than curative activity in murine (Urbina et al.,
2003a) and canine (Diniz et al., 2010) models of Chagas disease,
probably due to relatively short terminal plasma half-life of rav-
uconazole in mice (4.5 h) and dogs (8.8 h). However, the half-life
is much longer in humans (4–8 days) that, combined with a large
volume of distribution, make it possible that the tissue exposure
levels would be high enough in humans to be curative. Based on
these considerations, the Drugs for Neglected Diseases initiative
(DNDi) and Eisai Co. are partnering in a phase II trial of a pro-drug
Fig. 4. Crystal structure of T. cruzi CYP51 complexed with posaconazole, seen along the substrate access channel; protein in grey, posaconazole in bright green, heme in red.
Figure prepared with Molegro Molecular Viewer using coordinates from Protein Data Bank code 3K1O (Lepesheva et al., 2010a). (For interpretation of the references to color
in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 3. Structures of posaconazole and ravuconazole.
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532-eisai-and-dndi-enter-into-a-collaboration.html) (Clayton,
2010), which started in Bolivia in June 2011. Due to the simpler
chemical structure, it is believed that cost of goods might be less
of an issue for this candidate than for posaconazole.4. Anti-T. cruzi CYP51 inhibitors under development in
academia
Although repurposing an approved clinical drug (or a candidate
in clinical development) has obvious practical advantages, it
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Chagas drug that is sufﬁciently effective, safe, and affordable for
widespread use in populations with high prevalence of Chagas dis-
ease. As a consequence, we continue to see work by the Chagas re-
search community exploring other CYP51 inhibitors for anti-T.
cruzi activity. To this end, scientists at University of Washington
have been developing a class of imidazole containing molecules re-
lated to the investigational anticancer drug, tipifarnib (Hucke et al.,
2005; Kraus et al., 2009). Tipifarnib is an inhibitor of human pro-
tein farnesyl transferase (PFT) that was found to have a remarkable
in vitro activity against T. cruzi. It was determined that the activity
of the compound against T. cruzi cells was much greater than its
inhibitory effects on the T. cruzi PFT enzyme, and subsequent
experiments demonstrated that the primary mechanism of action
was a blockade of sterol biosynthesis via inhibition of CYP51
(Hucke et al., 2005). Since the inhibitory activity on PFT was unnec-
essary for its T. cruzi activity, analogs of tipifarnib were designed to
minimize this activity (which could lead to deleterious side effects)
while improving CYP51 inhibitory activity. Compounds were syn-
thesized that demonstrated sub-nanomolar inhibitory activity on
intracellular T. cruzi amastigotes and highly potent suppressive
activity on T. cruzi infection in the mouse model (Kraus et al.,
2009). The current lead compound (Fig. 5) combines the excellent
pharmacokinetic properties of tipifarnib (i.e. oral bioavailability
and good metabolic stability) with minimal PFT activity, and sub-
nanomolar potency on T. cruzi (Kraus et al., 2010). Efﬁcacy experi-
ments in mice are in progress.
Working with the same strategic aim, the group led by Lepesh-
eva and Waterman investigated a large variety of compounds as
potential CYP51 inhibitors using an HTS spectroscopic assay that
evaluates type II spectral responses to detect strong binders to
the 6th coordination position of the heme iron (Lepesheva et al.,
2007, 2008). However, it was found than in many cases the appar-
ent binding parameters determined by spectral titration did not
correlate with the inhibitory effects of the compounds on the
reconstituted enzyme activity; thus, the spectral hits had to be
conﬁrmed using the biochemical assay (Lepesheva et al., 2007,
2008). The best results of this approach have been those resulting
from a screen of a collection of azole derivatives of the Novartis Re-
search Institute (Vienna, Austria), which led to the identiﬁcation of
two potent b-phenyl imidazoles, VNF (a.k.a SDZ285604) and VNI
(Fig. 5), which produce a functionally irreversible inhibition of T.Fig. 5. Structures of novel T. cruzi CYP51 inhibitorcruzi and T. brucei CYP51s at a 1:1 inhibitor ratio. Such compounds
are remarkably selective for the Trypanosomatid enzymes (the hu-
man enzyme is only slightly affected by a 100-fold excess of the
inhibitors) (Lepesheva et al., 2008) and VNF (Fig. 5) can eradicate
T. cruzi ’s amastigote infection from cultured murine cardiomyo-
cytes at 1 lM (Lepesheva et al., 2010b). Although such selective
activity is promising, it remains to be seen whether VNF is as po-
tent as the antifungal triazoles discussed above. Interestingly, it
was also found that VNI binds to T. brucei CYP51 in a pose very sim-
ilar to that of posaconazole bound to T. cruzi CYP51, although with
less extensive interactions with the substrate access channel
(Lepesheva et al., 2010b); these ﬁndings may provide insights on
how to increase the potency of this class of compounds, while pre-
serving their selectivity. No in vivo studies of VNF or VNI have been
reported. Another approach by the same team led to the identiﬁca-
tion of a novel class of non-azole T. cruzi CYP51 inhibitors, based on
the pyridine-indomethacin amide scaffold (Konkle et al., 2009;
Lepesheva et al., 2008). Enzymatic studies showed that ChemDiv
C155-0123 (Fig. 5) was a potent but reversible inhibitor of T. cruzi
CYP51 (Lepesheva et al., 2008). However, the most potent com-
pound of this series was only able to fully eradicate amastigotes
from infected cardiomyocytes at 20 lM. Remarkably, ChemDiv
C155-0123 was independently identiﬁed by the team of Podust
and McKerrow, from a screen against Mycobacterium tuberculosis
CYP51, as a potent inhibitor of T. cruzi CYP51 (Lepesheva et al.,
2011; Chen et al., 2009). This compound was found to bind selec-
tively to T. cruzi CYP51 and to eradicate T. cruzi amastigotes from
infected mouse (J774) macrophages at 10 lM, with no toxicity
for the host cells. In a subsequent study (Doyle et al., 2010), the
same team reported that ChemDiv C155-0123 (referred to as
LP10) inhibited the synthesis of endogenous sterol in T. cruzi epim-
astigotes and induced partial cures in a murine model of acute Cha-
gas disease. If the ADME and toxicology proﬁle of this compound or
subsequent derivatives proves to be appropriate for human use it
could become an alternative to the commercial antifungal azoles
that now command the ﬁeld.5. Prospects for CYP51 inhibitors for Chagas disease
Future treatments for Chagas disease will need to address the
glaring inadequacies of the current therapeutics, benznidazole
and nifurtimox. First and foremost, these drugs have cure ratess (see text). Asterix () indicates chiral center.
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when the vast majority of individuals are diagnosed. Second, the
side effect proﬁle of current drugs makes completing full courses
of treatment difﬁcult due to patient intolerance. Third, the effec-
tiveness of these drugs in immune compromised Chagas patients
(e.g. organ transplant recipients or AIDS patients) is less than ideal.
The outcomes of the ongoing phase II clinical trials of posaconazole
and E1224 for Chagas disease will begin to provide answers to
whether CYP51 inhibitors will be an improvement upon the exist-
ing drugs. Based on clinical experience in patients with fungal
infections, posaconazole is likely to be much better tolerated than
the existing anti-Chagas drugs. Whether the anti-parasitic activity
of posaconazole in humans will be equivalent or better than that
observed in experimental animals remains the key unanswered
question (although the case report of the patient in Spain with
chronic Chagas disease compounded by immunosuppression cured
with posaconazole certainly points in this direction) and will not
likely be fully resolved with the current phase II studies. Nonethe-
less, such studies mark a belated but important step for advancing
our knowledge of CYP51 inhibitors for human T. cruzi infection.
If posaconazole proves to be successful in these trials and follow
up studies, it is likely to revolutionize the approach to treating Cha-
gas disease. In particularly, huge number of patients with chronic
asymptomatic infection, who are not currently receiving therapy
because of widespread disdain for current drugs, will likely be-
come candidates for anti-T. cruzi therapy to prevent the develop-
ment of the serious pathological manifestations resulting from
the persistence of the parasite in the infected organs. Then the is-
sue of affordability and availability will become paramount. As
indicated above the high cost of posaconazole may limit its use
in resource-limited regions unless its distribution is subsidized,
while for the case of ravuconazole (E1224) the price issue will
probably be less important (http://www.dndi.org/press-releases/
532-eisai-and-dndi-enter-into-a-collaboration.html). For this rea-
son, alternative, less expensive CYP51 inhibitors, described above,
may be necessary to address the needs of patients.
If posaconazole falls short in the clinical trials, will this be the
end of CYP51 inhibitors for Chagas disease? It certainlywill be a set-
back, but hopefully the results will guide future action to address
the shortcomings. Obviously, issues such as optimal dosing and
duration of treatment are likely to be sorted out in subsequent clin-
ical investigations. If satisfactory outcomes are not observed, this
could be because of sub-optimal pharmacokinetics, such as inade-
quate penetration into key tissues harboring parasites. These
ﬁndings would suggest the need to identify alternative CYP51
inhibitors with better-optimized pharmacokinetic properties. On
the other hand, if CYP51 inhibitors are inadequate as monotherapy,
could they serve as a component in combination chemotherapy for
Chagas disease? Unpublished data indicate that combinations of
posaconazole and benznidazole have synergistic activity in animal
models (Bahia et al., 2011). A combination strategy could poten-
tially allow for higher cure rates than with either drug alone, and
potentially with lower doses or shorter treatment courses for better
tolerability and lower cost. Other investigational drugs (such as
ergosterol biosynthesis inhibitors acting at a different step of the
biosynthetic pathway, e.g. squalene synthase (Urbina et al., 2004),
could also be partnered with posaconazole or another CYP51 inhib-
itor for potentially synergistic activity that could give it the boost it
may need. As with many other infectious diseases (e.g., malaria, TB,
HIV), combination chemotherapy is becoming standard of care to
optimize effectiveness and limit the development of resistance.
In conclusion, CYP51 inhibitors have been a topic of interest for
Chagas disease researchers for over 30 years. Small scale, poorly
controlled clinical studies with earlier generation antifungal drugs
(ﬂuconazole, ketoconazole, and itraconazole) left more questions
than answers (Apt et al., 1998; Urbina and Docampo, 2003). Fortu-nately, we are moving into a new era where highly potent and safe
anti-T. cruzi CYP51 inhibitors (posaconazole and E1224) will be
studied in well controlled trials in Chagas patients to provide data
that will inform future development for this class of compounds. It
is an exciting time for this ﬁeld.Acknowledgements
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